Showing results (191-200 of 10,340) with videos related to

Sort By:
Pageof 1,034
Annals of the Rheumatic Diseases|November 6, 2023
Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sjögren's syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trialThomas Dörner, Martin Kaul, Antónia Szántó, et al.
Annals of the Rheumatic Diseases|November 6, 2023
Subclinical giant cell arteritis increases the risk of relapse in polymyalgia rheumaticaEugenio De Miguel, Rositsa Karalilova, Pierluigi Macchioni, et al.
Annals of the Rheumatic Diseases|November 18, 2023
Expression quantitative trait loci analysis in rheumatoid arthritis identifies tissue specific variants associated with severity and outcomeKatriona Goldmann, Athina Spiliopoulou, Andrii Iakovliev, et al.
Annals of the Rheumatic Diseases|November 2, 2023
Ultra-rare genetic variation in relapsing polychondritis: a whole-exome sequencing studyYiming Luo, Marcela A Ferrada, Keith A Sikora, et al.
Annals of the Rheumatic Diseases|October 31, 2023
Data quality and patient characteristics in European ANCA-associated vasculitis registries: data retrieval by federated queryingKarl Gisslander, Matthew Rutherford, Louis Aslett, et al.
Annals of the Rheumatic Diseases|October 30, 2023
Extracting immunological and clinical heterogeneity across autoimmune rheumatic diseases by cohort-wide immunophenotypingHiroaki Tanaka, Yukinori Okada, Shingo Nakayamada, et al.
Annals of the Rheumatic Diseases|September 4, 2023
Global, regional and national temporal trends in prevalence for musculoskeletal disorders in women of childbearing age, 1990-2019: an age-period-cohort analysis based on the Global Burden of Disease Study 2019Fan Cao, Da-Peng Li, Guo-Cui Wu, et al.
Annals of the Rheumatic Diseases|September 1, 2023
Examining the biological pathways underlying clinical heterogeneity in Sjogren's syndrome: proteomic and network analysisJoe Scott Berry, Jessica Tarn, John Casement, et al.
Annals of the Rheumatic Diseases|September 11, 2023
Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL studyChristopher T Ritchlin, Laura C Coates, Iain B McInnes, et al.
Annals of the Rheumatic Diseases|September 12, 2023
Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2)Roy M Fleischmann, Désirée van der Heijde, Vibeke Strand, et al.
Pageof 1,034